A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: Results from a French nationwide study

Clinical Infectious Diseases

Volumn 57, Issue 12, 2013, Pages

  Epaulard, Olivier ^a,b   Villier, Céline ^a   Ravaud, Philippe ^c   Chosidow, Olivier ^d,e   Blanche, Stéphane ^f   Mamzer Bruneel, Marie France ^g   Thiébaut, Anne ^h   Leccia, Marie Thérèse ^a,i   Lortholary, Olivier ^j,k,l  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

^c HÔTEL DIEU   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f Service d'Immunologie et Hématologie Pédiatrique   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h Unité Mixte de Thérapie Cellulaire et Tissulaire   (France)

ⁱ INSERM   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k Centre d'Infectiologie Necker Pasteur   (France)

^l INSTITUT PASTEUR   (France)

more..

Author keywords

carcinoma; phototoxicity; skin; voriconazole

Indexed keywords

VORICONAZOLE;

ACTINIC KERATOSIS; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BLISTER; CHEILITIS; CLINICAL ARTICLE; DRUG SAFETY; ERYTHEMA; FEMALE; FRANCE; GRAFT RECIPIENT; HUMAN; LENTIGO; MALE; PHOTOTOXICITY; PRIORITY JOURNAL; PSEUDOPORPHYRIA; SKIN CARCINOMA; SKIN DEFECT; SKIN MANIFESTATION; SUN EXPOSURE; TREATMENT DURATION;

CARCINOMA; PHOTOTOXICITY; SKIN; VORICONAZOLE;

ADULT; AGED; COHORT STUDIES; DERMATITIS, PHOTOTOXIC; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; SKIN NEOPLASMS; TRIAZOLES; YOUNG ADULT;

EID: 84890018591     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit600     Document Type: Article

References (29)

1. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Ped Infect Dis J 2002; 21:240-8
2. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 3 - 2009 update. Bone Marrow Transplant 2011; 46:709-18
3. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: Results of the VOSIFI study. Haematologica 2010; 95:1762-8
4. Chen SC, Blyth CC, Sorrell TC, Slavin MA. Pneumonia and lung infections due to emerging and unusual fungal pathogens. Sem Respir Crit Care Med 2011; 32:703-16
5. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Review 2007; 20:695-704
6. Epaulard O, Leccia MT, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect 2011; 41: 639-45
7. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44:e55-6
8. Brunel AS, Fraisse T, Lechiche C, Pinzani V, Mauboussin JM, Sotto A. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy. AIDS 2008; 22:905-6
9. Vanacker A, Fabre G, Van Dorpe J, Peetermans WE, Maes B. Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. Am J Transplant 2008; 8: 877-80
10. Cowen EW, Nguyen JC, Miller DD, et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62:31-7
11. Epaulard O, Saint-Raymond C, Villier C, et al. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients. Clin Microbiol Infect 2010; 16:1362-4
12. Ibrahim SF, Singer JP, Arron ST. Catastrophic squamous cell carcinoma in lung transplant patients treated with voriconazole. Dermatol Surg 2010; 36:1752-5
13. Morice C, Acher A, Soufir N, et al. Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: A case report. Case Rep Med 2010; 2010:351084
14. Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29:1240-4
15. Zwald FO, Spratt M, Lemos BD, et al. Duration of voriconazole exposure: An independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38:1369-74
16. Feist A, Lee R, Osborne S, Lane J, Yung G. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012; 31: 1177-81
17. Singer JP, Boker A, Metchnikoff C, et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31:694-9
18. European Medicines Agency. Summary of product characteristics. Available at: Http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR Product-Information/human/000387/WC500049756.pdf. Accessed 16 August 2013
19. Hensen P, Muller ML, Haschemi R, et al. Predisposing factors of actinic keratosis in a north-west German population. Eur J Dermatol 2009; 19:345-54
20. Drake AL, Walling HW. Variations in presentation of squamous cell carcinoma in situ (Bowen's disease) in immunocompromised patients. J Am Acad Dermatol 2008; 59:68-71
21. Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 2007; 73:2020-6
22. Cheng MP, Paquette K, Lands LC, Ovetchkine P, Theoret Y, Quach C. Voriconazole inhibition of vitamin A metabolism: Are adverse events increased in cystic fibrosis patients? Ped Pulmonol 2010; 45:661-6
23. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65:253-61; quiz 262
24. Stern RS. Photocarcinogenicity of drugs. Toxicol Lett 1998; 102-103: 389-92
25. Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Sorensen HT, Karagas MR. Use of photosensitising diuretics and risk of skin cancer: A population-based case-control study. Br J Cancer 2008; 99: 1522-8
26. Traianou A, Ulrich M, Apalla Z, et al. Risk factors for actinic keratosis in eight European centres: A case-control study. Br J Dermatol 2012; 167(suppl 2):36-42
27. Sauvaigo S, Douki T, Odin F, Caillat S, Ravanat JL, Cadet J. Analysis of fluoroquinolone-mediated photosensitization of 2′-deoxyguanosine, calf thymus and cellular DNA: determination of type-I, type-II and triplet-triplet energy transfer mechanism contribution. Photochem Photobiol 2001; 73:230-7
28. Klecak G, Urbach F, Urwyler H. Fluoroquinolone antibacterials enhance UVA-induced skin tumors. J Photochem Photobiol 1997; 37: 174-81
29. Alberu J. Clinical insights for cancer outcomes in renal transplant patients. Transplant Proc 2010; 42:S36-40